Neratinib, trastuzumab + fulvestrant for HER2-mutant, HR+, metastatic breast cancer

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for tr...Подробнее

Neratinib Plus Fulvestrant for HER2 Mutant, Non-Amplified Metastatic Breast CancerПодробнее

GS4 10 Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastaticПодробнее

Neratinib-based combination therapy in HER2-Mutant lung cancerПодробнее

Dr. Mohammad Jahanzeb on Neratinib and Trastuzumab in HER2-Positive Breast CancerПодробнее

Final results from the phase 2 SUMMIT basket trial: targeting HER2+ advanced BTCs with neratinibПодробнее

Metastatic Breast Cancer Forum 2018: HER2-positive Breast Cancer | Dana-Farber Cancer InstituteПодробнее

Neratinib after trastuzumab-based adjuvant therapy in Her 2 positive breast cancer (ExteNET)Подробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

ELEANOR: real-world use of neratinib in HER2+, early breast cancerПодробнее

Neratinib in HER2+ Breast CancerПодробнее

Neratinib for Metastatic Breast CancerПодробнее

ELEANOR interim analysis: real-world study of adjuvant neratinib in HER2+/HR+ early breast cancerПодробнее

Dr. Esteva Discusses Neratinib Updates in HER2+ Breast CancerПодробнее

Neratinib/T-DM1 Doses Recommended for Phase II Trial in Breast CancerПодробнее

Dr. Tripathy Discusses Neratinib in HER2+ Breast CancerПодробнее

Optimal Timing for NeratinibПодробнее

Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancerПодробнее

Dr. Blackwell on Neratinib in HER2+ Breast CancerПодробнее